Could ADCs be a game-changer for oncology? New cancer drugs based on ADCs have shown promising results in shrinking hard-to-treat tumors in mice. This innovative therapy targets cancer cells' waste disposal system, leading to their self-destruction. 3 Key Takeaways: - This approach disrupts a novel cellular process, offering a fresh perspective on cancer treatment. - Early results in mice are encouraging, but further research is needed to assess safety and efficacy in humans. - This discovery highlights the continuous advancements in cancer research, offering hope for future breakthroughs. What are your thoughts on this new therapeutic approach? #LifeSciences #Oncology #CancerResearch #DrugDiscovery #Innovation #Breakthrough https://lnkd.in/eY-Bnrqf

🔬We’re thrilled to announce the results of the TOPGEAR trial on gastric and gastroesophageal junction adenocarcinoma. The study showed that the addition of preoperative chemoradiotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone. This breakthrough will impact clinical practice worldwide. Learn more here: https://lnkd.in/ggs3X8HQ Karin Haustermans, Florian Lordick, NHMRC Clinical Trials Centre, Canadian Cancer Trials Group, Trans Tasman Radiation Oncology Group (TROG Cancer Research), GI Cancer Institute & Australasian Gastro-Intestinal Trials Group, NEJM Group #CancerResearch #ClinicalTrials #GastricCancer #Oncology #Adenocarcinoma #ESMO24

Immunotherapy (IO) is a growing field in cancer research and represents a new paradigm in cancer care. In the last decade, it has become an established pillar of cancer treatment improving the prognosis of many patients. One common topic in the field of IO is the identification of suitable biomarkers that predict a patient’s response to IO. Auristone believes we are well positioned to support precision oncology through our Asian epigenomics database with analytical capabilities and focuses on predicting the benefits of IO to patients. Come meet with us at ASCO GI 2024, drop us a PM and we would love to share what we do! #ASCO24 #GI24 #immunotherapy #precisiononcology #epigenomics

Join Dr. Wafik S. El-Deiry, and Dr. Mark Gramling as they discuss the potential of immune response in future cancer treatments and the challenge of managing rapidly evolving oncology data. They explore how clinicians navigate new genetic insights and the continuous progress in cancer research. 🔍 Highlights: • Future potential of immune-based cancer cures • Navigating the ever-growing landscape of oncology data Listen in for insights on the evolving challenges and opportunities in oncology. #Oncology #CancerResearch #LARVOL

We presented new data at AACR Journals' 15th Annual Ovarian Cancer Research Symposium in Seattle highlighting the impact and inherent chemotherapy resistance of alterations in CCNE1, FBXW7, and PPP2R1A in patients with metastatic ovarian and endometrial cancers based on an analysis in ~2,000 patients from Cancer Genome Atlas Research Network and Memorial Sloan Kettering Cancer Center's Metastatic Events and Tropisms. Given the lack of treatment options for metastatic gynecologic cancer patients with these biomarkers, we look forward to reporting data from our MYTHIC dose expansion trial in Q4 2024. https://lnkd.in/eB9NfkiW #precisiononcology

Exciting new research in the field of bladder cancer! A recent systematic review and meta-analysis delves into the clinicopathological significance of B7-H3, a potential biomarker for prognosis and treatment in bladder cancer. The study uncovers key insights into B7-H3 expression in tumor tissues, patient age, and recurrence. However, the link to overall survival remains uncertain. A must-read for oncology professionals seeking in-depth knowledge of bladder cancer biomarkers. #BladderCancer #B

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: https://lnkd.in/gEyecuir #Oncology #Immunotherapy #Biomarkers

Advancing Cancer Therapy with Biomarkers! The integration of cancer biomarkers into treatment plans is revolutionizing oncology. By targeting specific molecular features like HER2 in breast cancer and ALK in lung cancer, we're seeing remarkable improvements in patient outcomes. Biomarkers ensure treatments are precise, effective, and personalized. Join us in the fight against cancer with cutting-edge, biomarker-driven therapies! #Oncology #CancerBiomarkers #PersonalizedTreatment #MedicalAdvances #HopeForPatients https://lnkd.in/dFAjZRmM

🌟 Excited to Share Insights from AACR 2024! 🌟 Attended an enlightening session: "Engineering T cells to eradicate tumors," led by Philip D. Greenberg from Fred Hutchinson Cancer Center. The focus was on revolutionizing T-cell therapy to fight cancer more effectively, tackling the complex challenges and potential breakthroughs. Dr. Greenberg's presentation underscored the power of scientific innovation in overcoming obstacles in cancer treatment. It was a motivational reminder of how far we've come and the promising future that lies ahead in oncology research. Inspired and ready to contribute more to this vital field! Let’s connect if you're passionate about cancer research or have insights on T-cell therapy. The conversation around the future of oncology is one I'm eager to continue. #AACR2024 #CancerResearch #Oncology #Innovation #FredHutch

🌐 Diagnostics, Volume 13, Issue 2 (January-2 2023) 🔬 THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer 🔍 Several studies indicate that THSD7A might play a role at least in the prognosis of different tumor types. FAK, a key player in prostate cancer progression, is being explored as a therapeutic target, particularly in advanced stages. 💡 This research investigates whether THSD7A expression impacts the expression of FAK in its unphosphorylated form. With evidence pointing to THSD7A’s involvement in FAK-dependent pathways, it opens the discussion of THSD7A as a potential therapeutic target in prostate cancer. 📖 Discover more: https://lnkd.in/d9kvcMH3 #THSD7A #FAK #ProstateCancer #Diagnostics